3SBio (HKEX:1530) is a leading biotechnology company in the People’s Republic of China founded in 1993. As a pioneer in the PRC biotechnology industry, 3SBio has extensive expertise in developing, manufacturing and marketing biopharmaceuticals. Three core products, TPIAO, Yisaipu and EPIAO are market leaders in the PRC. TPIAO is the only commercialized recombinant human thrombopoietin (rhTPO) product in the world. Yisaipu, a recombinant human tumor necrosis factor-α receptor II (TNFR) – IgG Fc fusion protein for the treatment of rheumatoid arthritis is the industry leader with a market share in excess of 60%. EPIAO, a recombinant human erythropoietin (rhEPO) product, together with the other rhEPO product acquired recently, SEPO, is the dominant market leader in the rhEPO market. In addition, 3SBio has more than 26 other products in the oncology, rheumatology, nephrology, dermatology and other therapeutic areas. 3SBio is focused on building an innovative product pipeline, with over 11 National Class 1 candidates under development.